Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.71 |
| ▸ | HTR2A | P28223 | 5/20 | 0.71 |
| ▸ | HTR2B | P41595 | 3/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17504260 | 1.00 | HTR2C (0.71) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL16122771 | 0.86 | HTR2C (0.71) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL31079387 | 0.83 | HTR2C (1.00) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL6364886 | 0.83 | HTR2C (1.00) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL16122500 | 0.82 | CHRM2 (0.52) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL17504350 | 0.82 | CHRM2 (0.52) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL31079572 | 0.81 | HTR2C (0.71) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL17504295 | 0.81 | HTR2C (0.70) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL16122506 | 0.81 | HTR2C (0.70) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL17504314 | 0.80 | HTR2C (0.62) | HTR2CHTR2AHTR2BCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670209-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160039819-A1 | MUSCARINIC AGONISTS | ALLERGAN, INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039819-A1 | MUSCARINIC AGONISTS | CHRM3, CHRM2, CHRM1 | HTR2C 386/4885HTR2A 352/4885HTR2B 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.